Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
Phillip McCarthy(Roswell Park Comprehensive Cancer Center), Claudia Linker, Craig C. Hofmeister(The Ohio State University), Edward A. Stadtmauer(University of Pennsylvania), Kouros Owzar(Duke University), K. C. Anderson, Hani Hassoun(Memorial Sloan Kettering Cancer Center), S. Giralt, Vera Hárs, David D. Hurd(Duke University)
Cited by 82
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
|Journal of Clinical Oncology|2001|898
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
|Journal of Clinical Oncology|1999|893